{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:36:00Z","timestamp":1740123360807,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10549-021-06440-z","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:06:31Z","timestamp":1637132791000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does definitive local therapy have a role in select HER2+\u2009de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?"],"prefix":"10.1007","volume":"191","author":[{"given":"Luderve","family":"Rosier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3218-9739","authenticated-orcid":false,"given":"Karen","family":"Daily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"6440_CR1","doi-asserted-by":"crossref","unstructured":"Lane WO, Thomas SM, Blitzblau RC, Plichta J, Rosenberger LHM, Fayanju O, Greenup RA (2019) Surgical resection of the primary tumor in women with de novo stage IV breast cancer. Ann Surg 537\u2013544","DOI":"10.1097\/SLA.0000000000002621"},{"key":"6440_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100118","volume-title":"De-novo metastatic breast cancers with or without primary tumor resection- a 10 year study","author":"M Co","year":"2019","unstructured":"Co M, Nga J, Kwonga A (2019) De-novo metastatic breast cancers with or without primary tumor resection- a 10 year study. Elsevier"},{"key":"6440_CR3","doi-asserted-by":"crossref","unstructured":"Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improve survival in metastatic breast cancer? Surgery","DOI":"10.1067\/msy.2002.127544"},{"key":"6440_CR4","doi-asserted-by":"crossref","unstructured":"Petrelli F, Barni S (2012) Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 29(5)","DOI":"10.1007\/s12032-012-0310-0"},{"key":"6440_CR5","doi-asserted-by":"crossref","unstructured":"Khan SA, Zhao F, Solin LJ, et al (2020) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol 38(suppl):abstr LBA2","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2"},{"issue":"13","key":"6440_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N et al (2015) Loco-regional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16(13):1380\u20131388","journal-title":"Lancet Oncol"},{"key":"6440_CR7","doi-asserted-by":"crossref","unstructured":"Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Gnant M (2019) Impact of breast surgery in primary metastasized breast cancer outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg 1163\u20131169","DOI":"10.1097\/SLA.0000000000002771"},{"issue":"11","key":"6440_CR8","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S et al (2018) Randomized trial comparing resection of primary tumor with no surgery in stage iv breast cancer at presentation: protocol MF07-01. Ann Surg Oncol 25(11):3141","journal-title":"Ann Surg Oncol"},{"key":"6440_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clbc.2017.04.002","volume":"17","author":"M Lambertini","year":"2017","unstructured":"Lambertini M, Ferriera AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepaine C (2017) Patterns of care and clinical outcomes of HER2-Positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multi-center retrospective cohort study. Clin Breast Cancer 17:601-610.e2","journal-title":"Clin Breast Cancer"},{"key":"6440_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kin S-B et al (2020) Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomized, placebo-controlled, phase 3 study. Lancet Oncol 21:519\u2013530","journal-title":"Lancet Oncol"},{"key":"6440_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.breast.2013.10.005","volume":"23","author":"V Rossi","year":"2014","unstructured":"Rossi V, Nole F, Redana S et al (2014) Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. The Breast. 23:44\u201349","journal-title":"The Breast."},{"key":"6440_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1634\/theoncologist.2018-0213","volume":"24","author":"Y Wong","year":"2019","unstructured":"Wong Y, Raghavendra A, Hatzis C et al (2019) Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24:313\u2013318","journal-title":"Oncologist"},{"key":"6440_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10552-016-0791-9","volume":"27","author":"L Tao","year":"2016","unstructured":"Tao L, Chu L, Wang L et al (2016) Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes Control 27:1127\u20131138","journal-title":"Cancer Causes Control"},{"key":"6440_CR14","doi-asserted-by":"crossref","unstructured":"Tripathy, D., Brufsky, A., Cobleigh, M., et al (2014) Abstract P3\u201307\u201314: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the systemic therapies for HER2-positive metastatic breast cancer registry study. SABCS","DOI":"10.1158\/1538-7445.SABCS14-P3-07-14"},{"key":"6440_CR15","doi-asserted-by":"crossref","unstructured":"Howlader N, Cronin K, Kurian A, et al (218) Differences in breast cancer survival by molecular subtypes in the United States. Cancer epidemiology biomarkers and prevention. 27(6)","DOI":"10.1158\/1055-9965.EPI-17-0627"},{"key":"6440_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","volume":"161","author":"B Leone","year":"2017","unstructured":"Leone B, Vallejo C, Romero A et al (2017) Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat 161:537\u2013548","journal-title":"Breast Cancer Res Treat"},{"key":"6440_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-017-9871-9","volume":"34","author":"D Press","year":"2017","unstructured":"Press D, Miller M, Liederbach et al (2017) De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis 34:457\u2013465","journal-title":"Clin Exp Metastasis"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06440-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T15:39:25Z","timestamp":1642433965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06440-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6440"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06440-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}